Drug
Gefitinib clinical trials
Also written Iressa and ZD1839.
- studies test it
- 239
- open now
- 6
- in phase 3
- 30
- first study started
- 2000
Keep track of what changes. Save the Gefitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
236 studies that test it; most in 2004 (43)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2001 | 18 |
| 2002 | 21 |
| 2003 | 37 |
| 2004 | 43 |
| 2005 | 21 |
| 2006 | 8 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 10 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 10 |
| 2013 | 6 |
| 2014 | 8 |
| 2015 | 6 |
| 2016 | 8 |
| 2017 | 5 |
| 2018 | 7 |
| 2020 | 2 |
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 56
- Phase 2
- 170
- Phase 3
- 30
- Phase 4
- 4
- No phase
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 67 · Other 172
AstraZeneca (49) · National Cancer Institute (NCI) (20) · Memorial Sloan Kettering Cancer Center (6) · University of Chicago (5) · M.D. Anderson Cancer Center (5) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Samsung Medical Center (4) · Massachusetts General Hospital (4)
Often tested with
Tested in the same studies.
Cisplatin (16) · Docetaxel (10) · Pemetrexed (7) · Erlotinib (6) · Gemcitabine (5) · Fluorouracil (5) · Irinotecan (5) · Carboplatin (4)
Studies
Open first, then newest update. How each study uses Gefitinib is read from its arms, and is right about nine times in ten.
Testing it · 239
- Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver CancerNot yet recruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT07829926Written as Gefitinib
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07477457Written as Gefitinib
- Therapy for Advanced NSCLC With EGFR 19delins MutationNot yet recruitingEarly Phase 1Fuzhou General HospitalNCT07458919Written as Icotinib/Gefitinib
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingPhase 1/2China Medical University HospitalNCT06071013Written as Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
- Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFRNot yet recruitingNot applicableQilu Pharmaceutical Co., Ltd.NCT03381430Written as Gefitinib
- Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC PatientsNot yet recruitingPhase 3Sun Yat-sen UniversityNCT03203590Written as Gefitinib
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingPhase 1/2Dana-Farber Cancer InstituteNCT03122717Written as Gefitinib
- A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung CancerCompletedPhase 1/2Stanford UniversityNCT00238628Written as Iressa
- Bioequivalence Study of Gefitinib Tablets Under Fasting ConditionsCompletedPhase 1Hunan Kelun Pharmaceutical Co., Ltd.NCT03050164Written as Gefitinib Tablet 250mg of Hunan Kelun
- Bioequivalence Study of Gefitinib Tablets Under Fed ConditionsCompletedPhase 1Hunan Kelun Pharmaceutical Co., Ltd.NCT03050177Written as Gefitinib Tablet 250mg of Hunan Kelun
- Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M NegativeCompletedPhase 1/2Sunshine Lake Pharma Co., Ltd.NCT03758287Written as Gefitinib
- A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung CancerTerminatedPhase 2Massachusetts General HospitalNCT03292133Written as Gefitinib
- ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung CancerCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT00328562Written as ZD1839 (Iressa)
- Treatment of Lung Adenocarcinoma With Bronchioloalveolar FeatureCompletedPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT00198380Written as Gefitinib
- A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell CarcinomaCompletedPhase 2University of ChicagoNCT01185158Written as ZD1839 (IRESSA)
- Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line ChemotherapyCompletedPhase 2Seoul Veterans HospitalNCT01485809Written as Gefitinib
- Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone TherapyTerminatedPhase 2University of NebraskaNCT00483561Written as Gefitinib plus etoposide
- BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder CancerTerminatedPhase 3NCIC Clinical Trials GroupNCT00352079Written as gefitinib
- Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular CarcinomaCompletedNot applicableRenJi HospitalNCT04642547Written as Lenvatinib and Gefitinib
- Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)CompletedPhase 2Fudan UniversityNCT01833572Written as Gefitinib
See all 239 studies that test Gefitinib →
Given in every arm · 32 — Gefitinib is usual care beside what is tested
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingPhase 3Eli Lilly and CompanyNCT02411448Written as Gefitinib
- Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneActive, not recruitingPhase 2Novartis PharmaceuticalsNCT03040973Written as Gefitinib
- Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)CompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT02856893Written as Gefitinib
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruitingPhase 1Novartis PharmaceuticalsNCT03333343Written as gefitinib
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingPhase 2AstraZenecaNCT03944772Written as Gefitinib
- Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib AloneCompletedPhase 1/2Spanish Lung Cancer GroupNCT01513174Written as Gefitinib
- A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT02039674Written as Gefitinib
- Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibStatus unknownPhase 2Second Affiliated Hospital of Nanchang UniversityNCT04358562Written as Gefitinib
- Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLCStatus unknownPhase 3Sun Yat-sen UniversityNCT04028778Written as Gefitinib
- A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2Eli Lilly and CompanyNCT01469000Written as Gefitinib
- Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin CancerCompletedPhase 2National Cancer Institute (NCI)NCT00126555Written as Gefitinib
- Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary AdenocarcinomaCompletedPhase 3Shanghai University of Traditional Chinese MedicineNCT02889692Written as Gefitinib®
- Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary AdenocarcinomaStatus unknownPhase 3Shanghai University of Traditional Chinese MedicineNCT02929693Written as gefitinib
- Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung CancerStatus unknownNot applicableThe First Affiliated Hospital of Soochow UniversityNCT03766490Written as Gefitinib
- Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder CarcinomaStatus unknownPhase 2Shanghai Jiao Tong University School of MedicineNCT02836847Written as Gefitinib
- Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLCTerminatedPhase 4Sichuan UniversityNCT02299765Written as Gefitinib
- Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2National Cancer Center, KoreaNCT00452244Written as gefitinib only
- Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung CancerCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00062062Written as gefitinib
- Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation AbundanceStatus unknownPhase 2Caicun ZhouNCT02930954Written as Gefitinib
- Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)Status unknownPhase 3Sichuan Provincial People's HospitalNCT02882984Written as Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib
Showing 20 of 32.
As the comparator · 15 — what is tested is compared with Gefitinib
- Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)CompletedPhase 3Yuhan CorporationNCT04248829Written as Gefitinib 250 mg
- AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedPhase 3AstraZenecaNCT02296125Written as Gefitinib 250 mg
- First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesCompletedPhase 2/3Alpha Biopharma (Jiangsu) Co., Ltd.NCT03653546Written as Gefitinib
- Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)Active, not recruitingPhase 3Allist Pharmaceuticals, Inc.NCT03787992Written as Gefitinib 250 mg
- A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsTerminatedPhase 3Astellas Pharma Global Development, Inc.NCT02588261Written as Gefitinib
- A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer PatientsStatus unknownPhase 3Beta Pharma ShanghaiNCT03866499Written as Gefitinib
- ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCActive, not recruitingPhase 3Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT04143607Written as Gefitinib
- ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.CompletedPhase 3PfizerNCT01774721Written as Gefitinib
- A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in PatientsStatus unknownPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT03849768Written as Gefitinib
- Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLCStatus unknownPhase 2Fudan UniversityNCT04425187Written as Gefitinib
- LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the LungCompletedPhase 2Boehringer IngelheimNCT01466660Written as gefitinib
- A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerStatus unknownPhase 3Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT04239833Written as Gefitinib
- Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR MutationStatus unknownPhase 3Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03856697Written as Gefitinib Tablets
- Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 MutationsCompletedPhase 3Chinese Society of Lung CancerNCT01024413Written as gefitinib
- Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsCompletedPhase 3Betta Pharmaceuticals Co., Ltd.NCT01040780Written as Gefitinib
Codes
What other systems call Gefitinib · ClinicalTrials.gg INT006655
- MeSH (NLM) D000077156GefitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S65743JHBSGEFITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 328134Confirmed FDA, Wikidata
- Wikidata Q417824gefitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1855GefitinibOne source FDA
- DrugBank DB00317One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077156 | Gefitinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S65743JHBS | GEFITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 328134 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417824 | gefitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1855 | Gefitinib | One source FDA |
| DrugBank | DB00317 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.